Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes. / Rumora, Amy E; Guo, Kai; Alakwaa, Fadhl M; Andersen, Signe T; Reynolds, Evan L; Jørgensen, Marit E; Witte, Daniel R; Tankisi, Hatice; Charles, Morten; Savelieff, Masha G; Callaghan, Brian C; Jensen, Troels S; Feldman, Eva L.

I: Annals of clinical and translational neurology, Bind 8, Nr. 6, 06.2021, s. 1292-1307.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Rumora, AE, Guo, K, Alakwaa, FM, Andersen, ST, Reynolds, EL, Jørgensen, ME, Witte, DR, Tankisi, H, Charles, M, Savelieff, MG, Callaghan, BC, Jensen, TS & Feldman, EL 2021, 'Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes', Annals of clinical and translational neurology, bind 8, nr. 6, s. 1292-1307. https://doi.org/10.1002/acn3.51367

APA

Rumora, A. E., Guo, K., Alakwaa, F. M., Andersen, S. T., Reynolds, E. L., Jørgensen, M. E., Witte, D. R., Tankisi, H., Charles, M., Savelieff, M. G., Callaghan, B. C., Jensen, T. S., & Feldman, E. L. (2021). Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes. Annals of clinical and translational neurology, 8(6), 1292-1307. https://doi.org/10.1002/acn3.51367

CBE

Rumora AE, Guo K, Alakwaa FM, Andersen ST, Reynolds EL, Jørgensen ME, Witte DR, Tankisi H, Charles M, Savelieff MG, Callaghan BC, Jensen TS, Feldman EL. 2021. Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes. Annals of clinical and translational neurology. 8(6):1292-1307. https://doi.org/10.1002/acn3.51367

MLA

Rumora, Amy E o.a.. "Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes". Annals of clinical and translational neurology. 2021, 8(6). 1292-1307. https://doi.org/10.1002/acn3.51367

Vancouver

Rumora AE, Guo K, Alakwaa FM, Andersen ST, Reynolds EL, Jørgensen ME o.a. Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes. Annals of clinical and translational neurology. 2021 jun;8(6):1292-1307. https://doi.org/10.1002/acn3.51367

Author

Rumora, Amy E ; Guo, Kai ; Alakwaa, Fadhl M ; Andersen, Signe T ; Reynolds, Evan L ; Jørgensen, Marit E ; Witte, Daniel R ; Tankisi, Hatice ; Charles, Morten ; Savelieff, Masha G ; Callaghan, Brian C ; Jensen, Troels S ; Feldman, Eva L. / Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes. I: Annals of clinical and translational neurology. 2021 ; Bind 8, Nr. 6. s. 1292-1307.

Bibtex

@article{3bec18921bc74b5281cd7cec14f76476,
title = "Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes",
abstract = "OBJECTIVE: The global rise in type 2 diabetes is associated with a concomitant increase in diabetic complications. Diabetic polyneuropathy is the most frequent type 2 diabetes complication and is associated with poor outcomes. The metabolic syndrome has emerged as a major risk factor for diabetic polyneuropathy; however, the metabolites associated with the metabolic syndrome that correlate with diabetic polyneuropathy are unknown.METHODS: We conducted a global metabolomics analysis on plasma samples from a subcohort of participants from the Danish arm of Anglo-Danish-Dutch study of Intensive Treatment of Diabetes in Primary Care (ADDITION-Denmark) with and without diabetic polyneuropathy versus lean control participants.RESULTS: Compared to lean controls, type 2 diabetes participants had significantly higher HbA1c (p = 0.0028), BMI (p = 0.0004), and waist circumference (p = 0.0001), but lower total cholesterol (p = 0.0001). Out of 991 total metabolites, we identified 15 plasma metabolites that differed in type 2 diabetes participants by diabetic polyneuropathy status, including metabolites belonging to energy, lipid, and xenobiotic pathways, among others. Additionally, these metabolites correlated with alterations in plasma lipid metabolites in type 2 diabetes participants based on neuropathy status. Further evaluating all plasma lipid metabolites identified a shift in abundance, chain length, and saturation of free fatty acids in type 2 diabetes participants. Importantly, the presence of diabetic polyneuropathy impacted the abundance of plasma complex lipids, including acylcarnitines and sphingolipids.INTERPRETATION: Our explorative study suggests that diabetic polyneuropathy in type 2 diabetes is associated with novel alterations in plasma metabolites related to lipid metabolism.",
keywords = "BETA-BLOCKER, METABOLOMICS, OUTCOMES, PEOPLE, PERIPHERAL NEUROPATHY, TRIAL",
author = "Rumora, {Amy E} and Kai Guo and Alakwaa, {Fadhl M} and Andersen, {Signe T} and Reynolds, {Evan L} and J{\o}rgensen, {Marit E} and Witte, {Daniel R} and Hatice Tankisi and Morten Charles and Savelieff, {Masha G} and Callaghan, {Brian C} and Jensen, {Troels S} and Feldman, {Eva L}",
note = "{\textcopyright} 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.",
year = "2021",
month = jun,
doi = "10.1002/acn3.51367",
language = "English",
volume = "8",
pages = "1292--1307",
journal = "Annals of clinical and translational neurology",
issn = "2328-9503",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes

AU - Rumora, Amy E

AU - Guo, Kai

AU - Alakwaa, Fadhl M

AU - Andersen, Signe T

AU - Reynolds, Evan L

AU - Jørgensen, Marit E

AU - Witte, Daniel R

AU - Tankisi, Hatice

AU - Charles, Morten

AU - Savelieff, Masha G

AU - Callaghan, Brian C

AU - Jensen, Troels S

AU - Feldman, Eva L

N1 - © 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

PY - 2021/6

Y1 - 2021/6

N2 - OBJECTIVE: The global rise in type 2 diabetes is associated with a concomitant increase in diabetic complications. Diabetic polyneuropathy is the most frequent type 2 diabetes complication and is associated with poor outcomes. The metabolic syndrome has emerged as a major risk factor for diabetic polyneuropathy; however, the metabolites associated with the metabolic syndrome that correlate with diabetic polyneuropathy are unknown.METHODS: We conducted a global metabolomics analysis on plasma samples from a subcohort of participants from the Danish arm of Anglo-Danish-Dutch study of Intensive Treatment of Diabetes in Primary Care (ADDITION-Denmark) with and without diabetic polyneuropathy versus lean control participants.RESULTS: Compared to lean controls, type 2 diabetes participants had significantly higher HbA1c (p = 0.0028), BMI (p = 0.0004), and waist circumference (p = 0.0001), but lower total cholesterol (p = 0.0001). Out of 991 total metabolites, we identified 15 plasma metabolites that differed in type 2 diabetes participants by diabetic polyneuropathy status, including metabolites belonging to energy, lipid, and xenobiotic pathways, among others. Additionally, these metabolites correlated with alterations in plasma lipid metabolites in type 2 diabetes participants based on neuropathy status. Further evaluating all plasma lipid metabolites identified a shift in abundance, chain length, and saturation of free fatty acids in type 2 diabetes participants. Importantly, the presence of diabetic polyneuropathy impacted the abundance of plasma complex lipids, including acylcarnitines and sphingolipids.INTERPRETATION: Our explorative study suggests that diabetic polyneuropathy in type 2 diabetes is associated with novel alterations in plasma metabolites related to lipid metabolism.

AB - OBJECTIVE: The global rise in type 2 diabetes is associated with a concomitant increase in diabetic complications. Diabetic polyneuropathy is the most frequent type 2 diabetes complication and is associated with poor outcomes. The metabolic syndrome has emerged as a major risk factor for diabetic polyneuropathy; however, the metabolites associated with the metabolic syndrome that correlate with diabetic polyneuropathy are unknown.METHODS: We conducted a global metabolomics analysis on plasma samples from a subcohort of participants from the Danish arm of Anglo-Danish-Dutch study of Intensive Treatment of Diabetes in Primary Care (ADDITION-Denmark) with and without diabetic polyneuropathy versus lean control participants.RESULTS: Compared to lean controls, type 2 diabetes participants had significantly higher HbA1c (p = 0.0028), BMI (p = 0.0004), and waist circumference (p = 0.0001), but lower total cholesterol (p = 0.0001). Out of 991 total metabolites, we identified 15 plasma metabolites that differed in type 2 diabetes participants by diabetic polyneuropathy status, including metabolites belonging to energy, lipid, and xenobiotic pathways, among others. Additionally, these metabolites correlated with alterations in plasma lipid metabolites in type 2 diabetes participants based on neuropathy status. Further evaluating all plasma lipid metabolites identified a shift in abundance, chain length, and saturation of free fatty acids in type 2 diabetes participants. Importantly, the presence of diabetic polyneuropathy impacted the abundance of plasma complex lipids, including acylcarnitines and sphingolipids.INTERPRETATION: Our explorative study suggests that diabetic polyneuropathy in type 2 diabetes is associated with novel alterations in plasma metabolites related to lipid metabolism.

KW - BETA-BLOCKER

KW - METABOLOMICS

KW - OUTCOMES

KW - PEOPLE

KW - PERIPHERAL NEUROPATHY

KW - TRIAL

U2 - 10.1002/acn3.51367

DO - 10.1002/acn3.51367

M3 - Journal article

C2 - 33955722

VL - 8

SP - 1292

EP - 1307

JO - Annals of clinical and translational neurology

JF - Annals of clinical and translational neurology

SN - 2328-9503

IS - 6

ER -